Effect of a clinical pharmacist-managed lipid clinic on achieving national cholesterol education program low-density lipoprotein goals

被引:62
作者
Bozovich, M
Rubino, CM
Edmunds, J
机构
[1] Drug Therapy Management Inc, Greensboro, NC 27401 USA
[2] Moses Cone Hlth Syst, Greensboro Area Hlth Educ Ctr, Dept Pharm Educ Res & Pharmacotherapy, Greensboro, NC USA
[3] Eagle Cardiol Grp, Greensboro, NC USA
[4] Univ N Carolina, Sch Med, Chapel Hill, NC USA
[5] Univ N Carolina, Sch Pharm, Chapel Hill, NC USA
来源
PHARMACOTHERAPY | 2000年 / 20卷 / 11期
关键词
D O I
10.1592/phco.20.17.1375.34895
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Despite national guidelines for treatment of hyperlipidemia, significant numbers of individuals with coronary artery disease are not treated to their National Cholesterol Education Program (NCEP) low-density lipoprotein (LDL) goals. The potential benefits of a clinical pharmacist-managed lipid clinic would be to improve rates of success in achieving these goals, improve drug adherence and compliance with therapy, and reduce cardiovascular events. All patients who had a documented history of coronary artery disease and were under the care of one cardiologist were treated in the pharmacist-managed lipid clinic. A second cardiologist provided usual care to a group of patients with coronary artery disease who served as controls. Patients in each arm were followed for a minimum of 6 months. A protocol for therapy changes in clinic patients was developed by the clinical pharmacist and approved by the cardiologist. At the end of 6 months, 69% of patients in the pharmacist-managed clinic achieved their LDL goal, compared with 50% of controls. Compliance with laboratory tests and drug regimens also improved in clinic patients. Compliance with lipid panels went from 8% 2 months before to 89% 2 months after the start of the study. At the end of 6 months compliance with laboratory work and refills was 80%. Thus the clinical pharmacist-managed clinic was highly successful in achieving NCEP goals for secondary prevention.
引用
收藏
页码:1375 / 1383
页数:9
相关论文
共 23 条
[21]  
Tonkin A, 1998, NEW ENGL J MED, V339, P1349
[22]  
*US GEN ACC OFF, 1996, GAOPEMD967 US GEN AC
[23]   Evidence for a new pathophysiological mechanism for coronary artery disease regression - Hepatic lipase-mediated changes in LDL density [J].
Zambon, A ;
Hokanson, JE ;
Brown, BG ;
Brunzell, JD .
CIRCULATION, 1999, 99 (15) :1959-1964